Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BLLN · against 232 other Healthcare companies of similar size
Ranked #164 of 233 · scores higher than 28% of peers
Bars: peers in each 10-point band of the valuation score22 peers with a valuation score of 30–39, including BLLN · Click a bar to see the companies
Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
| Metric | BLLN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 231 reported | 0.7% | 2.4% | 35% | 30% | |
| EBITDA yieldHigher is better · 230 reported | 1.0% | 4.5% | 28% | 50% | |
| Free cash flow yieldHigher is better · 128 reported | 0.6% | 0.8% | 48% | 20% | |
| Book yieldHigher is better · 232 reported | 10.4% | 25.8% | 21% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 4 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 4 | 428.3B JPY (≈$2.9B) | 98 | 59 | |
| 158 | 9.4B USD | 39 | 70 | |
| 158 | 2.6B USD | 39 | 32 | |
| 162 | 4.0B USD | 38 | 56 | |
| 162 | 9.1B USD | 38 | 74 | |
| 164 | 5.2B USD | 37 | 74 | |
| 164 | 8.6B USD | 37 | 30 | |
| 164 | 10.1B USD | 37 | 61 | |
| 164 | 2.7B USD | 37 | 44 | |
| 168 | 18.7B CNY (≈$2.6B) | 36 | 51 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score